IQVIA, a prominent global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry, has unveiled its latest innovation on June 12, 2024 – the One Home for Sites™ technology platform. This platform is designed to streamline the management of clinical trials for research sites, with the goal of reducing overwhelm and improving overall efficiency.
One Home for Sites™ serves as a single sign-on and dashboard for various systems and tasks that clinical research sites typically handle across multiple clinical trials. These tasks often involve numerous software applications, each requiring its own set of credentials, creating a significant burden for site staff. This technology overload ultimately impedes staff from dedicating more time to patient care and recruitment, as well as managing multiple trials simultaneously.
Recognizing this challenge, IQVIA’s One Home for Sites™ provides a solution by allowing pharmaceutical companies and their software vendors to integrate all necessary clinical applications into a single platform. Serving as a neutral aggregator, connector, and communicator, One Home for Sites™ aims to alleviate the burden on research sites, enabling them to devote more time to conducting research and delivering patient care.
Bernd Haas, senior vice president of IQVIA’s Digital Products and Solutions, expressed the company’s commitment to addressing industry challenges by stating, “With site capacity becoming a real challenge for the industry, we believe it is our role and responsibility to deliver a solution that brings industry stakeholders together and alleviates the burden on research sites.”
In the development of One Home for Sites™, IQVIA gathered input from over 100 site personnel to ensure that the platform meets their needs. Currently, IQVIA Prime Sites, which are committed to long-term relationships with IQVIA to improve clinical trial delivery, are piloting the platform to provide feedback and metrics on user experience and efficiencies gained.
Furthermore, IQVIA is collaborating with clinical technology vendors and pharmaceutical companies to implement an industry-wide approach to increase site capacity and accelerate the delivery of new treatments to patients.
Richard Staub, president of IQVIA Research & Development Solutions, emphasized the strategic value of One Home for Sites™ by stating, “Rather than competing with individual products and platforms, it enhances sites’ productivity by aggregating clinical trial systems.”
For more information about IQVIA’s One Home for Sites™ platform and its partnership program, visit www.iqvia.com/onehome.
In conclusion, IQVIA’s introduction of the One Home for Sites™ technology platform represents a significant advancement in simplifying the management of clinical trials for research sites. By addressing the challenges associated with technology overload, this platform aims to enhance operational efficiency and ultimately accelerate the development of new treatments for patients.